Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension

Abstract

Pulmonary arterial hypertension (PAH) is considered a disease of the pulmonary vasculature. Limited progress has been made in preventing or arresting progression of PAH despite extensive efforts. Our previous studies indicated that PAH could be considered a systemic disease since its pathology involves interplay of multiple organs. This, coupled with increasing implication of the gut and its microbiome in chronic diseases, led us to hypothesize that patients with PAH exhibit a distinct gut microbiome that contributes to, and predicts, the disease. Fecal microbiome of 18 type 1 PAH patients (mean pulmonary arterial pressure, 57.4, SD 16.7 mm Hg) and 13 reference subjects were compared by shotgun metagenomics to evaluate this hypothesis. Significant taxonomic and functional changes in microbial communities in the PAH cohort were observed. Pathways for the synthesis of arginine, proline, and ornithine were increased in PAH cohort compared with reference cohort. Additionally, groups of bacterial communities associated with trimethylamine/ trimethylamine N-oxide and purine metabolism were increased in PAH cohort. In contrast, butyrate-and propionate-producing bacteria such as Coprococcus, Butyrivibrio, Lachnospiraceae, Eubacterium, Akkermansia, and Bacteroides were increased in reference cohort. A random forest model predicted PAH from the composition of the gut microbiome with 83% accuracy. Finally, virome analysis showed enrichment of Enterococcal and relative depletion of Lactococcal phages in the PAH cohort. In conclusion, patients with PAH exhibit a unique microbiome profile that has the high predictive potential for PAH. This highlights previously unknown roles of gut bacteria in this disease and could lead to new therapeutic, diagnostic, or management paradigms for PAH.

Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension

“…This appears to include a role for the gut microbiome in PAH [41] with some bacterial taxa enriched in PAH stool samples and associated microbial metabolite changes in PAH patients [42]. In line with these findings we also show here perturbations and significant systemic gradients of microbial metabolites, including those involved in tryptophan, sphingomyelins and phosphatidylcholine metabolism.…”

Antihypertensive effects of exercise involve reshaping of gut microbiota and improvement of gut-brain axis in spontaneously hypertensive rat

“…They decrease in hypertensive animal and humans. 35,50 A reduction in butyrate-producing bacteria leads to a decrease in butyrate level, implicating hypertension pathology. This is consistent with the observations that butyrate is associated with reduced MAP in angiotensin IIinduced hypertensive animals, 35 and it also produces protective effects on neuroinflammation 51 and induces gut antibacterial peptides to counteract inflammatory and infectious processes.…”

ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities – Role of gut microbiota dysbiosis

“…This storm may be coincident with disruption of the enteric ACE2 axis, cumulating in the dysfunction of several physiologic systems and, ultimately, septic shock ( Chen et al, 2020a ; Guan et al, 2020 ). Coherently, a gut-lung axis has been proposed in the onset of pulmonary hypertension associated with a phenotype of gut dysbiosis and leaky gut linked with overactivation of the ACE/Ang II/AT1R axis due to ACE2 loss ( Kim et al, 2020 ). Host enterocytes continuous viral production and ACE2 depletion, as well as GM dysbiosis, may perpetuate a disrupted gut-lung axis, as previously suggested for SARS-CoV ( Leung et al, 2003 ).…”